Trial
NCT01239017
A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Regeneron Pharmaceuticals
Collaborators
Sanofi
Condition
Osteoarthritis
Intervention
REGN475
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-03-18